MX2021012461A - Procesos para preparar y usar un secretoma derivado de células madre mesenquimales. - Google Patents

Procesos para preparar y usar un secretoma derivado de células madre mesenquimales.

Info

Publication number
MX2021012461A
MX2021012461A MX2021012461A MX2021012461A MX2021012461A MX 2021012461 A MX2021012461 A MX 2021012461A MX 2021012461 A MX2021012461 A MX 2021012461A MX 2021012461 A MX2021012461 A MX 2021012461A MX 2021012461 A MX2021012461 A MX 2021012461A
Authority
MX
Mexico
Prior art keywords
stem cell
mesenchymal stem
processes
making
cell derived
Prior art date
Application number
MX2021012461A
Other languages
English (en)
Inventor
Spencer Alford
Original Assignee
Combangio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combangio Inc filed Critical Combangio Inc
Publication of MX2021012461A publication Critical patent/MX2021012461A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2053—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)

Abstract

La presente solicitud proporciona métodos y procesos para fabricar y usar un secretoma de células madre mesenquimales, así como métodos para tratar afecciones y/o trastornos oculares con el secretoma de células madre mesenquimales descrito en el presente documento.
MX2021012461A 2019-04-09 2020-04-07 Procesos para preparar y usar un secretoma derivado de células madre mesenquimales. MX2021012461A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962831371P 2019-04-09 2019-04-09
US201962929035P 2019-10-31 2019-10-31
US16/785,470 US10758571B1 (en) 2019-04-09 2020-02-07 Processes for making and using a mesenchymal stem cell derived secretome
US16/785,463 US10881693B2 (en) 2019-04-09 2020-02-07 Processes for making and using a mesenchymal stem cell derived secretome
PCT/US2020/027093 WO2020210248A1 (en) 2019-04-09 2020-04-07 Processes for making and using a mesenchymal stem cell derived secretome

Publications (1)

Publication Number Publication Date
MX2021012461A true MX2021012461A (es) 2022-01-04

Family

ID=72241604

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012461A MX2021012461A (es) 2019-04-09 2020-04-07 Procesos para preparar y usar un secretoma derivado de células madre mesenquimales.

Country Status (11)

Country Link
US (5) US10758571B1 (es)
EP (1) EP3952892A4 (es)
JP (1) JP2022526855A (es)
KR (1) KR20220047210A (es)
CN (1) CN114269359A (es)
AU (1) AU2020270892A1 (es)
BR (1) BR112021020450A2 (es)
CA (1) CA3136614A1 (es)
CL (1) CL2021002655A1 (es)
MX (1) MX2021012461A (es)
WO (1) WO2020210248A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758571B1 (en) 2019-04-09 2020-09-01 Combangio, Inc. Processes for making and using a mesenchymal stem cell derived secretome
IT201900022029A1 (it) * 2019-11-25 2021-05-25 Dompe Farm Spa Formulazioni oftalmiche
WO2021123320A1 (en) * 2019-12-20 2021-06-24 Dr. Kalali Prof. Mostafazadeh Dipl. Ing. Miedl (Kmm) Gesellschaft Bürgerlichen Rechts A composition and its use for a universal therapy against tumor cells
EP4132546A4 (en) * 2020-04-07 2024-05-01 Combangio Inc SECRETOME DERIVED FROM LYOPHILIZED MESENCHYMAL STEM CELLS AND USES THEREOF
EP3970732A1 (en) * 2020-09-17 2022-03-23 Hunan Yuanpin Cell Technology Co. Ltd Use of mesenchymal stem cells in the treatment of viral infections and/or complications caused by viral infections
CN112656816A (zh) * 2021-01-15 2021-04-16 浙江大学 一种负载外泌体的纤维蛋白胶及其应用
US20220378846A1 (en) * 2021-06-01 2022-12-01 U-Neuron Biomedical Inc. Use of secretome of amniotic fluid stem cell in the treatment of dry eye disease
CN113583950A (zh) * 2021-08-06 2021-11-02 合肥滴碧云生物科技有限公司 一种制备干细胞活性因子的方法及其应用
CN114350603B (zh) * 2022-01-23 2022-08-23 上海揽微赛尔生物科技有限公司 包含外泌体的间充质干细胞胞外基质及其制备和在细胞修复中的应用
CN115282286B (zh) * 2022-02-09 2023-05-02 天津医科大学眼科医院 一种治疗眼部新生血管类疾病的纳米复合体及应用
WO2024011252A2 (en) * 2022-07-08 2024-01-11 Combangio, Inc. Methods and assays for secretome activity analysis

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US20060165667A1 (en) 2004-12-03 2006-07-27 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
US20060222634A1 (en) 2005-03-31 2006-10-05 Clarke Diana L Amnion-derived cell compositions, methods of making and uses thereof
US8871198B2 (en) 2006-03-29 2014-10-28 Stemnion, Inc. Methods related to wound healing
KR20090043559A (ko) 2006-08-15 2009-05-06 에이전시 포 사이언스, 테크놀로지 앤드 리서치 중간엽 줄기세포 조절배지
WO2008024996A2 (en) 2006-08-24 2008-02-28 Johnstone Brian H Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
US20090054339A1 (en) 2007-08-22 2009-02-26 Marshall Vivienne S Novel cellular factor-containing solution compositions
WO2009045359A1 (en) 2007-10-01 2009-04-09 Stemnion, Inc. Skin replacement compositions and methods
KR101640381B1 (ko) 2008-02-22 2016-07-18 에이전시 포 사이언스, 테크놀로지 앤드 리서치 중간엽 줄기세포 입자
US20110158958A1 (en) 2009-12-07 2011-06-30 Sing George L Methods for treating ophthalmic disorders, diseases and injuries
WO2010110768A1 (en) 2009-03-23 2010-09-30 Regenetech, Inc. Composition and method for producing composition for constructing tissue, and tissue construct
EP2251028A1 (en) * 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor
ES2667265T3 (es) 2009-07-10 2018-05-10 Histogen, Inc. Medio condicionado y composiciones de matriz extracelular de células cultivadas en condiciones hipóxicas
US20110206647A1 (en) * 2010-02-25 2011-08-25 Abt Holding Company Modulation of Angiogenesis
US8911963B2 (en) 2010-04-05 2014-12-16 Medstar Health Research Institute, Inc. Conditioned medium obtained from stem cells and its use in therapy
FR2974201B1 (fr) 2011-04-18 2013-04-12 Inside Secure Circuit de multiplication de montgomery
US20120276215A1 (en) 2011-04-26 2012-11-01 Riordan Neil H Therapeutic Conditioned Media
WO2012175745A1 (en) 2011-06-24 2012-12-27 National University Of Ireland, Galway Cell secreted proteins for the treatment of myocardial infarction
ITTO20111183A1 (it) 2011-12-21 2013-06-22 Univ Degli Studi Torino Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia
SG11201404608WA (en) 2012-02-13 2014-09-26 Gamida Cell Ltd Mesenchymal stem cells conditioned medium and methods of generating and using the same
ITTO20120859A1 (it) * 2012-10-02 2014-04-03 Univ Degli Studi Torino Nuova applicazione terapeutica di un mezzo condizionato da cellule staminali mesenchimali placentari
CN103767985A (zh) * 2012-10-22 2014-05-07 吉林省霍普金斯药物研究院有限责任公司 人源血液或间充质干细胞分泌exosome的制备与应用
ES2697573T3 (es) * 2013-01-09 2019-01-25 United Therapeutics Corp Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas
US20140242043A1 (en) 2013-02-23 2014-08-28 Stemnion, Inc. Methods for preventing or treating optic neuritis
US20140255355A1 (en) 2013-03-07 2014-09-11 Stemnion, Inc. Methods for treating blepharitis
CL2013003066A1 (es) 2013-10-22 2014-07-25 Univ Chile Composicion para tratamiento de heridas porque comprende matriz soporte y células troncalesmesenquiámicas de gelatina de wharton; metodo para tratar heridas que comprende aplicar dicha composicion
US9636364B2 (en) 2013-12-04 2017-05-02 Stemnion, Inc. Methods for treating ocular contusion and blunt injury and traumatic injury to the optic nerve
US9464272B2 (en) 2013-12-12 2016-10-11 Stemnion, Inc. Cell-derived composition
WO2015179490A1 (en) 2014-05-21 2015-11-26 Stemnion, Inc. Treatment of diseases and conditions caused by increased vascular permeability
WO2016082882A1 (en) 2014-11-27 2016-06-02 Med Cell Europe Ag Secretomes and method for producing secretomes
EP3224348B1 (en) 2014-11-27 2021-07-14 Med Cell Bahamas Ltd. Secretomes and method for producing secretomes
US20180327713A1 (en) 2014-12-16 2018-11-15 Janssen Biotech, Inc. Treatment of retinal degeneration using progenitor cells
WO2016099949A2 (en) 2014-12-16 2016-06-23 Janssen Biotech, Inc. Treatment of retinal degeneration using progenitor cells
US20170080033A1 (en) 2014-12-16 2017-03-23 Janssen Biotech, Inc. Treatment of retinal degeneration using progenitor cells
KR101566450B1 (ko) 2015-04-03 2015-11-05 (유)스템메디케어 중간엽 줄기세포에서 단백질의 대량 생산 방법
TWI741980B (zh) 2015-04-07 2021-10-11 大陸商四川藍光英諾生物科技股份有限公司 一種生物磚及其用途
US20160361253A1 (en) 2015-06-13 2016-12-15 Noveome Biotherapeutics, Inc. Novel Methods for Delivering Therapeutic Agents to the Eye via Nasal Passages
WO2017001649A1 (en) 2015-07-02 2017-01-05 Med Cell Europe Ag Secretomes and method for producing secretomes
US20180220642A1 (en) 2015-07-29 2018-08-09 Indiana University Research And Technology Corporation Materials and methods for treating and evaluating ischemic and/or reperfusion-injured tissue and/or tissue susceptible to same
US20190046576A1 (en) * 2016-02-12 2019-02-14 Cell Care Therapeutics Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
KR20170111057A (ko) 2016-03-25 2017-10-12 (주)안트로젠 면역 질환 또는 염증성 질환의 예방 또는 치료용 중간엽줄기세포 배양액 및 이의 제조방법
RU2708329C2 (ru) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
WO2017217967A1 (en) 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Novel methods for delivering therapeutic agents to the eye via nasal passages
US20180028570A1 (en) 2016-08-01 2018-02-01 Ucl Business Plc Angiogenic Factors
KR20180024223A (ko) 2016-08-29 2018-03-08 사회복지법인 삼성생명공익재단 중간엽 줄기세포 분비 단백질을 포함하는 말초신경 세포 증식 촉진용 조성물
CN110087658A (zh) * 2016-10-12 2019-08-02 新加坡科技研究局 一种用于冻干外泌体的方法
WO2018102174A1 (en) 2016-12-01 2018-06-07 Janssen Biotech, Inc. Treatment of retinal degeneration using progenitor cells
WO2018131003A1 (en) 2017-01-16 2018-07-19 Cells For Cells, S.A Composition comprising a substantially pure population of multipotent stromal cells encapsulated in platelet-poor plasma (ppp)
US20180271914A1 (en) 2017-03-21 2018-09-27 Noveome Biotherapeutics, Inc. Methods for Reducing the Extent of Light-induced Tissue Inflammation and Injury
US20220088274A1 (en) 2017-05-18 2022-03-24 The Board Of Trustees Of The Leland Stanford Junior University Targeted in Situ Therapeutic Delivery of Secreted Factors from Stem Cells for Treatment of Damaged Tissue
CN111093681A (zh) 2017-07-16 2020-05-01 雷蒙特亚特特拉维夫大学有限公司 人类口腔粘膜干细胞分泌蛋白质组
US10364270B2 (en) 2017-10-02 2019-07-30 Pro Sunfun Biotech Research And Developmment Co., Ltd. Eye-care peptide, its composition and method of using the same
CN108517002A (zh) 2018-04-20 2018-09-11 命之本源医疗科技（北京）有限公司 一种干细胞培养上清分泌蛋白的稳定剂
US10758571B1 (en) 2019-04-09 2020-09-01 Combangio, Inc. Processes for making and using a mesenchymal stem cell derived secretome

Also Published As

Publication number Publication date
US20200325452A1 (en) 2020-10-15
CA3136614A1 (en) 2020-10-15
KR20220047210A (ko) 2022-04-15
US11654160B2 (en) 2023-05-23
US20210187034A1 (en) 2021-06-24
EP3952892A1 (en) 2022-02-16
WO2020210248A1 (en) 2020-10-15
BR112021020450A2 (pt) 2021-12-14
AU2020270892A1 (en) 2021-12-02
US20240033297A1 (en) 2024-02-01
US10758571B1 (en) 2020-09-01
CL2021002655A1 (es) 2023-01-20
US11129853B2 (en) 2021-09-28
EP3952892A4 (en) 2023-01-25
US10881693B2 (en) 2021-01-05
JP2022526855A (ja) 2022-05-26
CN114269359A (zh) 2022-04-01
US20210052656A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
MX2021012461A (es) Procesos para preparar y usar un secretoma derivado de células madre mesenquimales.
MX2022010425A (es) Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
MX2021000459A (es) Metodo para producir celulas t gamma y delta.
MX2020007591A (es) Homoserina deshidrogenasa modificada y procedimiento de produccion de homoserina o l-aminoacido derivado de homoserina mediante el uso de la misma.
MX2019011759A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando el mismo.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MX2021006564A (es) Sistemas activos dinamicos acromosomicos.
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
PH12021550558A1 (en) Modulators of pnpla3 expression
MX2022000893A (es) Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas.
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2019011758A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
MX2020011254A (es) Celulas t car anti-bcma para agotamiento de celulas de plasma.
PH12019502174A1 (en) Modulators of pcsk9 expression
MX2021000066A (es) Métodos y composiciones para la preparacion de tagatosa a partir de fructosa.
MX2021003450A (es) Metodos para tratar trastornos mieloproliferativos.
MX2021006463A (es) Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.
WO2021207282A3 (en) Lyophilized mesenchymal stem cell derived secretome and uses thereof
MX2021012634A (es) Neurogénesis.
MX2021003219A (es) Biomaterial que comprende celulas germinales derivadas de tejido adiposo y gelatina y metodo para producir el mismo.
WO2020047144A3 (en) Ophthalmic formulations, process for preparing the same and method for administering the same
MX2017014890A (es) Metodos de produccion de acetolactato-descarboxilasa (aldc).
MX2022006746A (es) Metodo y kit para el crecimiento celular.
MX2021015842A (es) Polipeptido variante de dihidrodipicolinato reductasa y procedimiento de produccion de l-treonina mediante el uso del mismo.
JOP20210108A1 (ar) معدِّلات تعبير irf5